FDA批准Fasenra(benralizumab)治疗6至11岁严重嗜酸粒细胞性哮喘儿科患者 AstraZeneca近日宣布,其创新药物Fasenra(通用名:benralizumab)已经获得美国食品和药物管理局(FDA)的扩展批准,可用于6至11岁患有严重嗜酸粒细胞性哮喘(Severe Eosinophilic Asthma,SEA)的儿科患者作为附加维持治疗。 这项新的适应症批准是基于开放标...
FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
FASENRA is an add-on maintenance treatment for patients 6 and older with severe eosinophilic asthma. See more. Not for sudden breathing problems. This Site is for US Patients FASENRA treats: Eosinophilic Asthma Approved use Patient Information Prescribing Information Cost & Affordability Instructions ...
April 11th, AstraZeneca’s FASENRA® (benralizumab) is approved by the US FDA for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype. FASENRA is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attract...
Uses Side effects Cost Before taking Dosage Interactions FAQ What is Fasenra?Fasenra (benralizumab) is an injectable monoclonal antibody that may be used as add-on therapy to treat severe eosinophilic asthma in adults and children aged 6 years and older. Fasenra is also approved to treat ...
Cost & Affordability Instructions For Use HCP Site En Español What is Eosinophilic Asthma? Why FASENRA? Taking FASENRA Savings Support Resources & Tools Sign Up For Info Dosing Calendar Your personal FASENRA Asthma Dose Calendar If you have just been prescribed FASENRA, or you’ve been taking ...
FASENRA is an add-on maintenance treatment for patients 6 and older with severe eosinophilic asthma. See more. Not for sudden breathing problems. This Site is for US Patients FASENRA treats: Eosinophilic Asthma Approved use Patient Information Prescribing Information Cost & Affordability ...
“Expanding options for children whose quality of life has been drastically impacted by severe eosinophilic asthma with the help of FASENRA is an exciting step in our mission to revolutionise asthma care.” Last month, the Japanese Ministry of Health, Labour and Welfare approved AstraZeneca’sTruq...